

# Synthesis of Co-drugs for Cancer Immunotherapy


A. Antonucci<sup>1</sup>, Meggie Danielson<sup>1</sup>, Alice De Vos<sup>1</sup>, Hannah Slocumb<sup>1</sup>, Professor Vy Dong<sup>1\*</sup>, Prof Thomas Burke<sup>1\*</sup>

<sup>1</sup> University of California, Irvine, California, United States


E-Mail presenting author: antonuca@uci.edu

Immunotherapies have emerged as a standard treatment for various types of cancer. This report two different receptors with small molecule agonists for immunotherapy. Preliminary data from the Burke lab at UCI demonstrates that administering agonists together creates a synergistic effect. We plan to synthesize a library of co-drugs that can be selectively cleaved in tumors. The co-drugs will have less off-target effects, which will facilitate their intravenous delivery, enabling an anti-cancer effect against a wide variety of cancer indications.

## Creating a Library of Co-drugs



Over 16 possible co-drugs from initial linker designs.



Interchangeable STING+DRUG agonists and linkers provide a platform to synthesize a library of codrugs.

Figure 1 : Program overview and drug/linker combinations.